Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.

Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Stenzel B, Steiner E, Oldridge D, Kitabayashi N, Banerjee S, Chen JY, Schäfer G, Horninger W, Lee C, Rubin MA, Klocker H, Demichelis F.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):229-39. doi: 10.1158/1055-9965.EPI-09-1018.

2.

Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.

Henríquez-Hernández LA, Valenciano A, Foro-Arnalot P, Álvarez-Cubero MJ, Cozar JM, Suárez-Novo JF, Castells-Esteve M, Fernández-Gonzalo P, De-Paula-Carranza B, Ferrer M, Guedea F, Sancho-Pardo G, Craven-Bartle J, Ortiz-Gordillo MJ, Cabrera-Roldán P, Rodríguez-Melcón JI, Herrera-Ramos E, Rodríguez-Gallego C, Lara PC.

Urol Oncol. 2015 Jul;33(7):331.e1-7. doi: 10.1016/j.urolonc.2015.04.003.

PMID:
25960412
3.

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E.

Eur Urol. 2016 Apr;69(4):601-9. doi: 10.1016/j.eururo.2015.06.054.

PMID:
26215610
4.

The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.

Choi SY, Kim HJ, Cheong HS, Myung SC.

Korean J Urol. 2015 Jan;56(1):19-30. doi: 10.4111/kju.2015.56.1.19.

5.

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.

Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J.

J Urol. 2013 Aug;190(2):615-9. doi: 10.1016/j.juro.2013.03.024.

PMID:
23499746
6.

Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Zhang A, Zhang J, Plymate S, Mostaghel EA.

Horm Cancer. 2016 Apr;7(2):104-13. doi: 10.1007/s12672-016-0250-9. Review.

PMID:
26797685
7.

Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.

Li X, Huang Y, Fu X, Chen C, Zhang D, Yan L, Xie Y, Mao Y, Li Y.

Mutagenesis. 2011 May;26(3):371-83. doi: 10.1093/mutage/geq103.

8.

Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.

Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, Pow-Sang J.

Urology. 2007 Aug;70(2):374-9.

PMID:
17826523
9.
10.

Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.

Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C.

Clin Cancer Res. 2014 Feb 1;20(3):576-84. doi: 10.1158/1078-0432.CCR-13-1100.

11.

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

Lunn RM, Bell DA, Mohler JL, Taylor JA.

Carcinogenesis. 1999 Sep;20(9):1727-31.

12.

SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.

Choubey VK, Sankhwar SN, Carlus SJ, Singh AN, Dalela D, Thangaraj K, Rajender S.

Asian Pac J Cancer Prev. 2015;16(3):1033-6.

13.

Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.

Poniah P, Mohamed Z, Apalasamy YD, Mohd Zain S, Kuppusamy S, Razack AH.

Int J Clin Exp Med. 2015 Oct 15;8(10):19232-40.

14.

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.

Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T.

Int J Cancer. 2001 Jun 1;92(5):683-6.

15.

Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.

Allen NE, Reichardt JK, Nguyen H, Key TJ.

Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):578-81.

16.

Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.

Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, Biron S, Luu-The V, Tchernof A.

J Endocrinol. 2006 Dec;191(3):637-49.

18.

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

Neslund-Dudas C, Bock CH, Monaghan K, Nock NL, Yang JJ, Rundle A, Tang D, Rybicki BA.

Prostate. 2007 Nov 1;67(15):1654-63.

19.

SRD5A polymorphisms and biochemical failure after radical prostatectomy.

Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E.

Eur Urol. 2011 Dec;60(6):1226-34. doi: 10.1016/j.eururo.2011.06.020.

PMID:
21715084
20.

VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ.

Clin Cancer Res. 2008 May 15;14(10):3223-9. doi: 10.1158/1078-0432.CCR-07-4894.

Items per page

Supplemental Content

Support Center